Bristol Myers Faces Renewed, $6.7 Billion Lawsuit Over Delayed Cancer Drug
The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by dragging its heels in seeking approval of the drugs, including the cancer drug Breyanzi, by specified deadlines. It said Bristol Myers did this to avoid a big payout.
AbbVie tumbles on drug test disappointment, Bristol-Myers gains
AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of Bristol-Myers Squibb (BMY), a competitor which makes a similar drug, have jumped. Market Domination Hosts Julie Hyman and Josh Lipton outline what investors need to know.
Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...
2don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Here are two brilliant options along those lines: CVS Health ( CVS 0.44%) and Bristol Myers Squibb ( BMY -1.03%). Find out ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to ...
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
Try Now>> See today’s best-performing stocks on TipRanks >> Read More on BMY: Bristol-Myers Squibb NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback